This inventor holds 3 USPTO granted patents and 8 published patent applications and 1 EPO patent. Top assignees: University Of Louisville Research Foundation, Inc., University of Virginia Patent Foundation. Active years: 2008-2016.
Location History:
- Louisville, KY (US) (2008)
- Chicago, IL (US) (2015 - 2016)
Company Filing History:
3 out of 398 
1 out of 1,043 
Years Active: 2008-2016
Title: David Gozal: Innovator in Sleep Apnea Diagnosis
Introduction
David Gozal is a prominent inventor based in Chicago, IL (US), known for his significant contributions to the field of medical diagnostics. He holds a total of 3 patents, focusing primarily on methods for diagnosing obstructive sleep apnea (OSA). His work has the potential to greatly impact the diagnosis and treatment of this condition, particularly in children.
Latest Patents
Gozal's latest patents include innovative methods and kits for diagnosing obstructive sleep apnea. These patents detail processes wherein a biological sample is collected from a subject, such as a human child, and the amount of a Urocortin III peptide is determined from the sample. Additionally, the patents provide methods for diagnosing OSA by measuring the levels of Urocortin III peptide alongside other peptides, including Uromodulin, Orosomucoid 1, and Kallikrein 1, in a biological sample.
Career Highlights
Throughout his career, David Gozal has worked with esteemed organizations such as the University of Louisville Research Foundation, Inc. and the University of Virginia Patent Foundation. His experience in these institutions has allowed him to advance his research and contribute to the field of sleep medicine.
Collaborations
Gozal has collaborated with notable colleagues, including Saeed A. Jortani and Roland Valdes, Jr. These partnerships have fostered a collaborative environment that enhances the development of innovative diagnostic methods.
Conclusion
David Gozal's work in the field of obstructive sleep apnea diagnosis exemplifies the importance of innovation in medical research. His patents and collaborations reflect a commitment to improving health outcomes for individuals affected by this condition.